What's in GenSight Biologics's pipeline?

GenSight Biologics has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with GenSight Biologics's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/gensight-biologics.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

GenSight Biologics — Portfolio Competitive Intelligence Brief

GenSight Biologics pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
GS010	GS010	phase 3	Gene therapy (AAV-mediated mitochondrial gene therapy)	ND4 gene (NADH dehydrogenase subunit 4)	Ophthalmology / Rare Genetic Disease

Therapeutic area mix

Ophthalmology / Rare Genetic Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for GenSight Biologics:

Cite this brief

Drug Landscape (2026). GenSight Biologics — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gensight-biologics. Accessed 2026-05-16.